Canada is holding back its 1-shot J & J COVID-19 vaccine. Here you need to know


Quality concerns over a batch of Canada’s Johnson & Johnson COVID-19 vaccines have halted the rollout of the shot just days before the country’s health agency deploys to the country’s toughest region.

On Friday, Health Canada announced that it was withdrawing the J-J vaccine, a one-shot dose that experts and health officials considered important to prevent the spread of the virus, amid a third wave of pandemics. After the spread, it was revealed that batches of parts were made at the same Baltimore plant where millions of other supplements were spoiled for the US market.

Read more:

Health Canada is holding the first batch of Jammu and Kashmir COVID-19 vaccines on quality control issues

In a statement, the agency said that a “narcotic” that would undergo further processing to become the final J&J shot was made at the Emergency Biosolution Plant in Baltimore, and later in a separate location for completion. Shipped and then shipped to Canada. .

Story continues under advertisement

The plant was previously cited by the US Food and Drug Administration (FDA) for several violations, including cleaning and sterilization as well as the possibility of cross-contamination. That agency has since ordered the plant to stop producing more Jammu and Kashmir vaccines until it addresses violations and manufacturing errors, resulting in a 15 million dose of destruction.


Click to play video: 'Global National: May 1'



Global National: 1 May


Global National: 1 May

Canadians are eagerly waiting for hotspots across the country to expect 300,000 doses on Monday, with some hotspot leaders expressing disappointment over the vaccine’s delay as cases continue at record highs in some provinces.

Here you have to know about the J & J COVID-19 vaccine.

Will the vaccine affect vaccination?

Health Canada, in its statement, did not provide any timeline as to when the vaccine batch review would be completed.

Story continues under advertisement

Health Canada, which is working with Janssen and the FDA on reviewing the batch, said the vaccines would only be released if it was “satisfied” that they met the department’s health standards.

Read more:

Johnson & Johnson’s vaccine is coming to Canada. How do we make the best use of it?

University of Toronto bioethicist Carey Bowman also said that she and everyone would not really be able to give a timeline as to when that review would be completed.

According to him, the news of Health Canada’s pull of the vaccine could also have another consequence – vaccine inhibition.

Recent reports of rare adverse events, including hemorrhage, have arisen after patients have taken AstraZeneca or J&J shots. Bowman and several other public health officials and experts have said that reports have given rise to vaccine hesitation around the country, even after repeated voices that such incidents are still very rare.

Bowman, however, said that there are actually two ways that one can see the implications of Health Canada’s prohibition for a vaccine.


Click to play video: 'Canada plans more aid as India registers COVID-19 deaths'



Canada plans more aid as India kills record COVID-19


Canada plans more aid as India kills record COVID-19

A person can either see this as another potential problem with taking the vaccine – or see it as a way that Health Canada’s system for protecting and screening vaccines that actually work.

Story continues under advertisement

Bowman said that people would interpret this as either more “trouble” on the vaccine front, or the fact that Health Canada’s system is protecting us.

Read more:

Most Canadians Say Whether They Get It: COVID-19 Vaccine Instrument Type

“But I think it will contribute to the vaccine ideologically because we know that there are many people who are hesitant about the vaccine.” … But you know, I think for a lot of people, including me to some extent, it shows that the system has some checks and balances and security measures in place, and that’s a very good thing. “

How effective is the vaccine

Results from the Phase 3 trials of Johnson & Johnson in late January suggested that its vaccine reduced COVID-19 by 85 percent and severely prevented 100% virus-related hospitalization or death.

In March, following the approval of the vaccine by Health Canada, the agency’s chief medical adviser Supriya Sharma said that about 20 percent of participants in clinical trials were 65 or older, and that safety or efficacy compared to younger There were no differences. group.


Click to play video: 'Vaccine waits to increase key supplies as vaccines roll out'



Vaccine waits for major supply boost as vaccines drop out


Vaccine waits for major supply boost as vaccines drop out

The shot was 72 percent effective at preventing COVID-19 infection after four weeks in US trials of J&J, although this efficacy fell below the 66 percent average from other global trials – including a South African review that included a The more convertible version was included.

Story continues under advertisement

In comparison, Pfizer and Moderna had 95 percent efficacy results in their respective tests, but were tested against previous recurrence of the virus and not against the increasingly prevalent and more infectious strains today. “For vaccines, keeping their stance that the best vaccine was the first one going into your arm.


Click to play video: 'COVID-19 Transition Increases Unaffiliated Youth in America'



COVID-19 infection increases among unaffiliated youth in America


COVID-19 infection increases among unaffiliated youth in America
Although not necessarily how effective J&J Shot is at preventing serious consequences, this vaccine causes a very large lead over the others, making it much easier to transport – only between 2C and 8C in the refrigerator. Need to be kept. At least three months.

Read more:

80% of Canadians plan to receive COVID-19 vaccine, but security fears create fear: public opinion

On the other hand, Pfizer is required to store between -70C and Moderna between -25C and -15C. AstraZeneca’s storage temperature is also similar to J & J’s, between 2C and 8C. The makeup of the J&J vaccine was also different from the mRNA used in Pfizer and Moderna. Using a non-replicating viral vector, similar to AstraZeneca, Schott uses a harmless virus that cannot copy itself – instead using ours as a vector tell our cells to show them the COVID-19 key. There is a need to make spike proteins.


Click to play video: 'Johnson & Johnson resume COVID-19 vaccine'



US resumes Johnson & Johnson COVID-19 vaccine


US Johnson & Johnson COVID-19 Vaccine Resumed – April 24, 2021
The immune system then recognizes the protein and then produces antibodies, then allows one’s body to be protected from an attack when exposed to the virus again.

Adverse reactions and bleeding?

Since a new report published by the US Center for Disease Control and Prevention (CDC), it has been found that only three of the 13,725 incidents reported through the Health Agency’s Vaccine Advance Events Reporting System after receiving the Jammu and Kashmir vaccine The percentage is classified as severe.

According to the CDC, as of April 21, a total of 17 blood clotting incidents in patients who experienced low blood platelet levels were found to be out of approximately eight million vaccinations.

Four of those in the venous sinuses of the brain received blood clotting reactions, and three were found elsewhere in the bodies of women who were under 60 years of age.

Read more:

Johnson & Johnson’s Vaccine Approved in Canada How Does It Compare to Others?

Story continues under advertisement

The review released on Friday stated that the vaccine’s overall “safety profile” was seen in its clinical trials.

“A rare but serious adverse event that occurs predominantly in women, blood clots in large vessels with low platelet counts were rapidly detected by the US Vaccine Safety Surveillance System,” the researchers write in the report.

“Common and rare adverse events continue to be monitored after the receipt of all COVID-19 vaccines, including the Janusan COVID-19 vaccine.”

The agency’s report also included 88 deaths after taking the vaccine, three of which occurred in patients with “cerebral venous sinus thrombosis”, but noted that none of the other deaths “had a connection with vaccination. “.


Click to play video: 'Immunization Acceleration'



Vaccination acceleration


Vaccination acceleration

On Monday, Health Canada updated the J & J COVID-19 vaccine product label to include a “very rare” risk of bloodclotting.

Story continues under advertisement

“So far, we have received three out of four vaccines that have issues … but I personally wouldn’t be surprised if it’s a matter of time until all of them have issues, because once you’re on millions of people Let these things roll. – I think that’s going to happen, “Bowman said.

Although the rest of Canada’s 10 million pre-order supplements are coming at a later date, 300,000 arrived in Canada at the end of April, when several million vaccines from other companies such as Pfizer and Moderna were scheduled to arrive. Upcoming week – The best question came up for which J&J supplements to use.

Public health officials and experts await the deployment of Janusan Shot to reach areas or groups of people who may face barriers to receiving a second dose.

Read more:

Hazdu ‘laser-focused’ on community COVID-19 proliferation amid calls for tougher boundaries

Infectious Disease Specialist Dr. Suman Chakraborty told the Canadian Press in April that the dynamics of the vaccine would enable it to reach more targeted populations.

“You can transport the vaccine there and just boom, boom, boom, get it into people’s arms,” ​​he said, noting that such vaccines could be used extensively in mobile vaccine clinics. Who vaccinate hard-suffering communities and essential workers.

Story continues under advertisement

“Time doesn’t help – we really wanted to start (vaccinate) the necessary workers as quickly as possible. … But this is something you can do (easily) with J&J.”

In a previous interview with Global News, infectious disease specialist Drs. Isaac Bogoche said the vaccine “removes barriers that may prevent people from coming back for a second vaccination.”


Click to play video: 'Vaccination Rate Continually Low among New People in Canada: Study'



Vaccination rates among newcomers consistently low in Canada: study


Vaccination rates among newcomers consistently low in Canada: study

“We know that there are some populations who will have more challenges – through no fault of their own – to return for a second dose, such as populations in prison, populations in shelters, migrant farmwork. They will all be ideal candidates, “Said Bogoche.

Experts have also stated that a one-shot vaccine can open the door for home vaccinations to homebound people, like elderly people, who may be mobile.

Story continues under advertisement

Yet despite its benefits, public health units will not see this vaccine anytime soon – even as Canada catches a third wave, filling ICUs and setting daily case records.

“In my understanding Johnson and Johnson were specifically earmarked for hotspot areas – many that I had seen in Western Canada – and that slowed everything down because Monday’s plan was for a number of places that would actually have these hotspots. Throw yourself into the Jammu and Kashmir rollout in the areas. Bowman said, “It is all on hold now.”

“This is another delay for Canada.”

– wCanadian Press and Global News’ ith files by Rachel D’Amore and Saba Aziz

View link »


© 2021 Global News, a division of Chorus Entertainment Inc.

.

Latest articles

Related articles